Clinical and morphological features of different types of Castleman’s disease


Aim. To study the clinical features of Castleman’s disease (CD) and to elaborate therapeutic approaches in its different morphological types. Subjects and methods. The clinical and laboratory data were studied in 59 prospectively examined patients and 17 retrospectively examined ones with CD who had been treated at the Outpatient Department, Hematology Research Centre, in 1996 to 2014. There were a total of 37 men (median age, 36 years) and 39 women (median age, 34 years). The diagnosis was established from the results of histological and immunohistochemical examinations of removed lymph nodes (LN) or tumors in all the cases. Results. A hyaline vascular variant (HVV) with local LN involvement was diagnosed in 38 (50%) patients; a plasma cell variant (PCV) was in 38 (50%); among the latter, 17 (22%) patients were found to have local involvement and 21 (28%) had generalized (multicentric) involvement (multicentric Castleman’s diseases (MCD)). Five (24%) patients with MCD were established to be infected with human herpesvirus type 8 (HHV-8). HVV was more frequently diagnosed in women (4%) than in men (29%); PCV was equally common in both men (47%) and women (53%); MCD was statistically significantly more frequently encountered in men (86%) than in women (14%) (p=0.05). The basic involvement areas in local HVV and PCV were peripheral (38%), mediastinal (29), retroperitoneal (18%), abdominal (9%), and small pelvic (6%) LNs. HVV and local PCV were benign and these were cured by surgical removal of LNs involved in the pathological process. MCD took its aggressive course with obvious constitutional symptoms, generalized lymphadenopathy, hepatosplenomegaly, hypergammaglobulinemia, autoimmune hemolysis, thrombocytopenia, and involvement of extranodal foci in the pathological process. MCD transformation to plasmablastic lymphoma was observed in 4 of the 5 HHV8-positive patients and followed by a poor outcome. The prognosis of untreated MCD was unfavorable. In a number of cases prednisolone monotherapy worsened prognosis and the MCD patients receiving timely multiple-drug R-CHOP or R-VD chemotherapy could achieve sustained remission (the 5-year overall survival was 55%). Conclusion. CD must be included into the differential diagnosis of lymphadenopathies. When specific treatment is performed, the prognosis of HVV and local PCV is favorable: the disease is surgically cured in 95% of cases. Multidrug chemotherapy according to the B-cell lymphoproliferative disease program is indicated for the treatment of MCD: sustained remission can be achieved by the use of R-CHOP or R-VD programs. The HHV-8-positive variants of MCD increase the probability of transforming the disease to incurable plasmablastic lymphoma. Overall, prognosis and therapy choice in HIV-negative patients with CD depend on the histological variant of the disease, the extent of a tumor, and HHV-8 infection.


  1. Castleman B, Thowne VW. Case records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011. New Engl J Med. 1954;250:26-30.
  2. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822-830.
  3. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972;29(3):670-683.
  4. Flendring JA. Benign giant lymphoma: Clinicopathologic correlation study, in Clark RL, Cumley RS. The Year book of cancer. Chicago: Year book; 1986:296.
  5. Gaba AR, Stein RS, Sweet DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978;69(1):86-90.
  6. Martin JM, Bell B, Ruether BA. Giant lymph node hyperplasia (Castleman’s disease) of hyaline vascular type. Clinical heterogeneity with immunohistologic uniformity. Am J Clin Pathol. 1985;84(4):439-446.
  7. Frizzera G, Peterson BA, Bayrd ED, Goldman A. A systemic lymphoproliferative disorder with morphologic features of Castleman’s disease: clinical findings and clinicopathologic correlation in 15 patients. J Clin Oncol. 1985;3(3):1202.
  8. Frizzera G. Castleman’s disease and related disorders. Semin DiagnPathol. 1988;5(4):346-364.
  9. Hanson CA, Frizzera G, Patton DF, Peretson BA, McClain KL, Gajl-Peczalska KJ, Kersey JH. Clonal rearrangement for immunoglobulin and T-cell receptor genes in systemic Castleman’s disease: association with Epstein Barr virus. Am J Pathol. 1988;131(1):84-91.
  10. Soulier J, Grollet L, Oksenhendler E, Miciea J-M, Cacoub P, Baruchel A, Brice P, Clauvel J-P, d’Agay M-F, Raphael M, Sigaux F. Molecular analysis of clonality in Castleman’s disease. Blood. 1995;86(3):1131-1138.
  11. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Lee T, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74(4):1360-1367.
  12. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266(5192): 865-1869.
  13. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. Lytic growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med. 1996;2(3):342-346.
  14. El-Osta HE, Kurzrock R. Castleman’s disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497-511.
  15. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br JHaematol. 2005;129(1):3-17. Review.
  16. Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF. The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer. 1999;85(3):706-717.
  17. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology Am Soc Hematol Educ Program. 2004:283-296.
  18. Kim JE, Kim JC, Park IA, Kim WH, Seo JW, Jang JJ, Kim CW, Park SH, Lee HS, Chi JG, Kim YI, Ham EK. Clinicopathologic study of Castleman’s disease in Korea. J Korean Med Sci. 2000;15(4):393-398.
  19. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean JHematol. 2012;47(3):163-177.
  20. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv AnatPathol. 2009;16(4):236-246.
  21. Talat N, Schulte KM. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16(9):1316-1324.
  22. Menke DM. Ly-1b cells and Castleman disease. Blood. 2000;96(4):1614-1616.
  23. Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, Weiss RA, Isaacson PG, Boshoff C. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95(4):1406-1412.
  24. Ioachim HL, Howard R. Ioachims lymph node pathology. Textbook and color atlas. Philadelphia: JB Lippinott Co; 2006: Chapter 43:246-253.
  25. Меликян А.Л., Капланская И.Б., Корнева Е.П., Франк Г.А. Болезнь Кастлемана. Терапевтический архив 2005;7:48-53.
  26. Меликян А.Л. Болезнь Кастлемана. Атлас. Опухоли лимфатической системы. Под ред. Воробьева А.И., Кременецкой А.М. М.; 2007:259-262.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies